NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Krsnaa Diagnostics released its Q2 & H1 FY27 earnings call transcript, highlighting that H1 FY27 revenue crossed the ₹500 crore mark to reach ₹507 crore, up 27% YoY. Trade receivables elevated to approximately ₹470 crore due to government disbursement delays, though management sees visibility on ₹200 crore in Q3 collections. Payables jumped from ₹63 crore to ₹230 crore alongside project enhancements, and Rajasthan tender lab implementation reached 75%-80%. The retail segment achieved operational breakeven in September 2026, with an aim to exit FY27 with positive EBITDA.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 & H1 FY27 earnings conference call held on November 03, 2026.
ஏன் இது முக்கியம்Provides granularity on operational execution (75-80% completed in Rajasthan), working capital stretch (receivables at ₹470 crore), and retail break-even timelines.
H1 FY27 Revenue: ₹507 கோடிH1 FY27 YoY Revenue Growth: 27%Total Receivables as of Sep 30: ₹470 கோடிExpected Q3 Collections: ₹200 கோடிRajasthan Project Implementation: 75% முதல் 80% வரைவர்த்தக செலுத்தவேண்டியவை: ₹230 கோடி
📅 குறுகிய காலம்Market focus will remain on working capital cycles, particularly whether the guided ₹200 crore government cash inflow is realized in Q3.
📈 நீண்ட காலம்Shifting mix toward cash-based retail and cash PPPs (targeted at 40-45% of revenue) could materially insulate the company from government payment delays and improve ROCE.
⚠ அபாய எச்சரிக்கைகள்
High working capital drag with receivables at ~₹470 crore (~58% of TTM revenue)
Sharp increase in trade and project payables to ₹230 crore
EBITDA margin moderation from initial costs of scaling large tenders like Rajasthan
👀 கவனிக்க வேண்டியவை
Track whether the projected ₹200 crore receivable collection materializes in Q3 results to ease working capital pressure, alongside progress in achieving EBITDA positivity in the retail vertical.
Krsnaa Diagnostics Wins Up to 15-Year Cash-Based PPP Project for 3 MCD Hospitals in Delhi
Krsnaa Diagnostics has received a Letter of Award dated November 2, 2026, from the Municipal Corporation of Delhi (MCD) to establish and operate CT Scan and MRI facilities across three public hospitals. The project follows a cash-collection PPP model with a concession tenure of 10 years, extendable by up to 5 years (up to 15 years total). Execution includes signing the agreement within 30 days and achieving commercial operation within 180 days of site handover. Contract consideration is not disclosed upfront as revenue depends on actual patient scan volumes.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa Diagnostics secured a new multi-year concession from MCD to install and run CT/MRI setups across three Delhi hospitals under a cash-collection framework.
ஏன் இது முக்கியம்Expands Krsnaa's footprint into Delhi public healthcare under a cash-collection model, which reduces reliance on state government disbursement cycles that previously stretched working capital.
Number of hospital project sites: 3Base concession tenure: 10 yearsExtension option: up to 5 yearsCOD implementation timeline: within 180 days of Site HandoverAgreement execution timeline: within 30 daysOrder value: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Positive sentiment from geographic expansion into the National Capital and contract accretion, with formal agreement signing due in 30 days.
📈 நீண்ட காலம்Strengthens Krsnaa's long-term cash-collection PPP pipeline over 10-15 years, supporting operational revenue growth while avoiding credit delays common in direct government billing.
⚠ அபாய எச்சரிக்கைகள்
Execution delays in site handover or OEM equipment delivery
Volume-dependent revenue realization (no guaranteed minimum billing specified)
👀 கவனிக்க வேண்டியவை
Track the signing of the Service Provider Agreement within 30 days and subsequent site handover notices to monitor the 180-day operationalization timeline.
Q2 FY27 Revenue Up 32% YoY to ₹271 Cr, PAT Rises 3% to ₹24.6 Cr Amid Upfront Expansion Costs
Krsnaa Diagnostics reported a 32% YoY growth in Q2 FY27 revenue to ₹271 crore (INR 2,710 Mn) compared to ₹206 crore in Q2 FY26. EBITDA grew 20% YoY to ₹71.9 crore, though EBITDA margins contracted by 200 bps to 27% due to upfront fixed costs of newly deployed Rajasthan laboratories ahead of full capacity utilization. PAT saw a modest rise of 3% YoY to ₹24.6 crore, impacted by higher finance costs and depreciation from asset additions. The retail business grew 35% YoY to ₹23.5 crore, contributing 9% of total revenues.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa reported its Q2 FY27 performance showing accelerating test volumes (+85%) but compressed margins due to upfront expansion overheads in Rajasthan.
ஏன் இது முக்கியம்Demonstrates rapid volume and top-line scaling in PPP and retail segments, though bottom-line growth is currently muted by initial fixed-cost drag, higher depreciation, and finance costs.
📅 குறுகிய காலம்Margin compression and higher financing charges may temper near-term earnings sentiment despite robust 32% top-line growth.
📈 நீண்ட காலம்Expansion into specialized testing (PET CT) and ramp-up of the Rajasthan mega project provide structural volume runway, with margin recovery contingent on asset utilization.
⚠ அபாய எச்சரிக்கைகள்
Trade receivables increased sharply to ₹474.56 crore (up from ₹295.51 crore in Mar 2026), reflecting stretched government payment cycles
Margin dilution from high initial fixed costs and channel partner/collection fees
👀 கவனிக்க வேண்டியவை
Track operating leverage and margin recovery as the Rajasthan integrated pathology project ramps up utilization, alongside monitoring working capital and receivables collection from state governments.
Krsnaa Diagnostics approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The auditor's limited review report highlighted an income tax demand order of Rs 62.69 crore (INR 626.90 million) across AY 2017-18 to AY 2023-24 following search proceedings. The company has deposited Rs 10.28 crore (INR 102.77 million) under protest and is filing appeals with the Income Tax Appellate Tribunal (ITAT). Management considers the tax demands untenable with no expected material financial impact.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa Diagnostics released its Q2 FY27 interim results and formally disclosed moving to ITAT against a cumulative tax demand of Rs 62.69 crore.
ஏன் இது முக்கியம்The Rs 62.69 crore tax demand represents approximately 64% of TTM PAT (Rs 98 crore), posing an overhang if appeals are ruled unfavorably, although operations and cash flows remain ongoing.
Income tax demand: INR 626.90 millionTax demand vs TTM PAT: ~64%Tax deposited under protest: INR 102.77 millionCash and cash equivalents (Standalone): INR 669.27 millionSubsidiary revenue (Q2): INR 473.47 million
📅 குறுகிய காலம்Market attention will focus on the ongoing appeal process with ITAT regarding the Rs 62.69 crore tax dispute and underlying quarterly operational performance.
📈 நீண்ட காலம்The company's core PPP model expansion and retail diagnostics growth strategy remain the primary structural drivers once legacy tax disputes are resolved.
⚠ அபாய எச்சரிக்கைகள்
Income tax dispute of Rs 62.69 crore pending before ITAT
High client concentration in government health departments with stretched receivables
👀 கவனிக்க வேண்டியவை
Track the outcome of appeals filed with the Income Tax Appellate Tribunal (ITAT) regarding the Rs 62.69 crore demand, and examine detailed revenue and margin trends from the full Q2 financial tables.
Krsnaa Diagnostics Allots 16.21 Lakh Warrants at ₹566/share to Promoters
Krsnaa Diagnostics has allotted 16,21,000 fully convertible warrants at an issue price of ₹566 each on a preferential basis to promoter and promoter group entities, representing a total issue size of ₹91.75 crore. The company has collected 25% upfront subscription money totaling ₹22.94 crore, with the remaining 75% payable upon conversion within 18 months. Upon full conversion, the promoter and promoter group stake will increase from 27.11% to 29.70%. The warrant issue price of ₹566 represents a modest premium of 6.3% over the current market price of ₹532.7.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa Diagnostics issued 16.21 lakh convertible warrants to promoters at ₹566 each, receiving ₹22.94 crore as 25% upfront subscription.
ஏன் இது முக்கியம்Demonstrates promoter capital commitment at a premium to market price and increases promoter holding towards 30%, while injecting up to ₹91.75 crore in equity capital over 18 months.
Total warrants allotted: 16,21,000Warrant issue price: ₹ 566/-Upfront amount received (25%): ₹ 22,93,71,500/-Total fundraise value: ₹91.75 கோடிTotal fundraise vs Market Cap: ~5.3%Post-conversion promoter stake: 29.70%
📅 குறுகிய காலம்Positive sentiment driver as promoters infuse capital at ₹566, above the prevailing market price of ₹532.7, without immediate dilution of equity capital.
📈 நீண்ட காலம்Strengthens the balance sheet and funds ongoing geographic expansions in Rajasthan and retail pathology, while consolidating promoter control from 27.11% to 29.70%.
⚠ அபாய எச்சரிக்கைகள்
Minor equity dilution of ~4.8% on fully diluted share capital upon full conversion
Warrant holders could forfeit the 25% upfront money if the stock trades significantly below ₹566 at the end of 18 months
👀 கவனிக்க வேண்டியவை
Track the deployment of the initial ₹22.94 crore proceeds into ongoing capex (such as Rajasthan and Maharashtra expansions) and watch for subsequent tranche conversions over the 18-month tenure.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
BSE Approves Issuance of 16.21 Lakh Convertible Warrants at Rs 566 to Promoters
Krsnaa Diagnostics has received a corrected in-principle approval from BSE Limited for issuing 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group. The warrants are priced at Rs 566 each (convertible into equity shares of face value Rs 5 each), representing a total fundraising amount of approximately Rs 91.75 crore. This capital infusion accounts for roughly 5.3% of the company's current market cap of Rs 1,741 crore. The filing rectifies factual errors noted in BSE's earlier approval letter dated October 08, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுBSE issued a corrected in-principle approval letter rectifying factual errors from its prior approval dated October 08, 2026.
ஏன் இது முக்கியம்The Rs 91.75 crore promoter infusion bolsters net worth, strengthens the balance sheet (current debt at Rs 531 crore), and signals promoter commitment to growth initiatives.
Convertible Warrants: 16,21,000Issue Price per Warrant: Rs 566Face Value per Share: Rs 5Total Fundraise vs Market Cap: ~5.3%
📅 குறுகிய காலம்Administrative clarity enables the company to proceed with preferential allotment formalities without regulatory hitches.
📈 நீண்ட காலம்Upon full conversion, promoter holding will increase marginally from the current 27.11%, supporting ongoing retail and PPP expansion plans.
⚠ அபாய எச்சரிக்கைகள்
Minor equity dilution of ~4.8% upon eventual conversion into equity shares
Subscription and conversion timelines span up to 18 months
👀 கவனிக்க வேண்டியவை
Track shareholder and final regulatory approvals, along with the timeline for allotment and upfront receipt of 25% warrant subscription money.
Krsnaa Diagnostics Secures In-Principle Approval for ₹91.75 Cr Promoter Warrant Issue at ₹566/Share
Krsnaa Diagnostics has received in-principle approval from NSE and BSE for the preferential issue of 16,21,000 convertible warrants to promoters at ₹566 per share, aggregating to approximately ₹91.75 crore. The issue price of ₹566 represents a ~6.4% premium over the current market price of ₹532.0. The total potential capital infusion of ₹91.75 crore represents roughly 5.3% of the company's current market cap of ₹1,730 crore and 9.2% of its net worth (₹992 crore). The approval is subject to customary listing conditions and compliance with SEBI insider trading and ICDR regulations.
உச்சம் நம்பிக்கை
என்ன மாறியதுStock exchanges granted in-principle approval to issue 16.21 lakh preferential convertible warrants to the promoter group.
ஏன் இது முக்கியம்Increases promoter skin in the game at a premium to the current market price while potentially injecting ₹91.75 crore in equity capital to support ongoing expansions.
Total warrants: 16,21,000Issue price per share: Rs. 566முக மதிப்பு: Rs. 5Total fundraise value: ~₹91.75 கோடிFundraise vs Market Cap: ~5.3%
📅 குறுகிய காலம்Positive sentiment driver as promoters are infusing capital at ₹566, above the prevailing market price of ₹532.
📈 நீண்ட காலம்Strengthens equity base and increases promoter holding (currently 27.11%), aiding funding for network expansion across Rajasthan and Maharashtra.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~4.9% upon full warrant conversion
Rectification of factual errors in BSE letter still pending
👀 கவனிக்க வேண்டியவை
Track the receipt of the rectified in-principle approval from BSE and subsequent board allotment timelines for the 18-month warrant conversion window.
Krsnaa Diagnostics Approves Sale of Equipment for Up to ₹120 Crore to Transition Asset-Light
Krsnaa Diagnostics' Board has approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore. This asset monetization represents approximately 14.7% of its TTM revenue (₹816 crore) and 12.1% of its net worth (₹992 crore). The initiative aims to shift the company toward an asset-light, capital-efficient model and recycle capital toward core diagnostics and growth opportunities. The assets involved are unencumbered freehold items, and the company stated there will be no material adverse impact on operations or P&L.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved the monetization of unencumbered diagnostic equipment worth up to ₹120 crore to move toward an asset-light model.
ஏன் இது முக்கியம்Unlocking ₹120 crore can significantly improve liquidity, reduce debt (currently ₹531 crore), and enhance ROCE without impairing core testing operations.
Equipment sale limit: up to ₹120 croreSale value vs TTM revenue: ~14.7%Sale value vs Net worth: ~12.1%Sale value vs Total Debt: ~22.6%
📅 குறுகிய காலம்Positive sentiment driver as the capital release improves liquidity and provides balance sheet flexibility.
📈 நீண்ட காலம்Supports a structural shift toward a higher-ROCE, asset-light operating structure, enabling self-funded expansion into retail diagnostics.
⚠ அபாய எச்சரிக்கைகள்
Execution risk regarding closure of deals with prospective buyers at expected valuations
Potential operational dependency if equipment is leased back or third-party service arrangements change
👀 கவனிக்க வேண்டியவை
Track the execution timeline, buyer details, and final realized consideration from the Operations Committee, as well as how proceeds are deployed (debt reduction vs. retail expansion).
Krsnaa Diagnostics Approves Preferential Issue of 16.21 Lakh Warrants to Promoters via Postal Ballot
Krsnaa Diagnostics shareholders have approved a Special Resolution via Postal Ballot for the issuance of up to 16,21,000 warrants convertible into equity shares on a preferential basis to the Promoter and Promoter Group. The remote e-voting concluded on September 17, 2026, with 92.69% of votes cast in favor and 7.31% against. The infusion will increase promoter stake from the current 27.11% level upon conversion, signaling promoter commitment. Key issue terms such as warrant pricing and total fundraise amount were not specified in this filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders officially passed the Special Resolution approving the preferential allotment of up to 16.21 lakh convertible warrants to the promoter group.
ஏன் இது முக்கியம்Increases promoter skin-in-the-game from the existing 27.11% stake and provides fresh growth/equity capital to fund operations or capex.
Warrants to be issued: 16,21,000ஒரு பங்கின் முக மதிப்பு: Rs.5/- eachApproval percentage (in favour): 92.6895%Cut-off date: ஆகஸ்ட் 14, 2026
📅 குறுகிய காலம்Neutral to slightly positive sentiment as the resolution passed comfortably with >92% shareholder support, confirming promoter capital backing.
📈 நீண்ட காலம்Equity dilution will be accompanied by promoter ownership expansion, strengthening capital base for retail footprint and PPP contract buildouts.
⚠ அபாய எச்சரிக்கைகள்
Dilution to minority shareholders upon warrant conversion
Issue price and valuation basis not stated in this voting disclosure
👀 கவனிக்க வேண்டியவை
Track subsequent filings for the issue price, total funds raised, allotment timelines, and warrant exercise schedule.
Krsnaa Signs 15-Year Concession Agreement for 4 PET-CT Centers in Punjab
Krsnaa Diagnostics has signed a Concession Agreement with the Department of Health & Family Welfare, Government of Punjab, following its August 14, 2026 Letter of Award. The project entails developing, operating, and maintaining PET-CT diagnostic facilities at 4 selected Government Hospitals under a DBFOT (Design, Build, Finance, Operate, Maintain and Transfer) model. This marks Krsnaa's entry into the high-end PET-CT oncology diagnostics segment, structured on a cash-based user-fee model across a 15-year tenure. While total contract value was not disclosed upfront due to scan volume dependencies, it expands Krsnaa's diagnostic offerings beyond its existing 186 CT/MRI centers and 120 pathology labs.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa completed all formalities to execute the definitive 15-year Concession Agreement for 4 PET-CT centers in Punjab.
ஏன் இது முக்கியம்Enters a new high-value diagnostic segment (PET-CT/oncology) via a cash-based PPP model, securing a 15-year revenue stream while diversifying from traditional CT/MRI and pathology.
Number of hospital locations: 4Concession period: 15 yearsLetter of Award date: ஆகஸ்ட் 14, 2026Contract consideration: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Neutral to mildly positive sentiment as the agreement is formalized; market will look for capex requirements and rollout timelines.
📈 நீண்ட காலம்Strengthens long-term revenue visibility via a multi-year cash-collection PPP model, providing entry into oncology diagnostics without working-capital stretch common to reimbursement tenders.
⚠ அபாய எச்சரிக்கைகள்
DBFOT capex execution risk and equipment procurement dependency
Volume-dependent revenue realization (no guaranteed minimum scan volume disclosed)
👀 கவனிக்க வேண்டியவை
Track the capital expenditure outlay required for the 4 PET-CT setups and monitor the operational commissioning timeline across Punjab hospitals over upcoming quarters.
Krsnaa Diagnostics Faces Aggregate Disputed Tax Demand of ₹62.69 Cr Across 7 Assessment Years
Krsnaa Diagnostics has received appellate orders from CIT(Appeals), Pune under Section 250 of the Income-tax Act, 1961 for Assessment Years 2017-18 through 2023-24. The orders reflect an aggregate disputed demand of ₹62.69 Cr, with appeals dismissed for four years (AY18 to AY21) and partly allowed for three years (AY22 to AY24). The disputed demand represents approximately 64% of the company's TTM PAT of ₹98 Cr and 6.3% of its net worth (₹992 Cr). The company intends to appeal against these orders before the Income Tax Appellate Tribunal (ITAT).
உச்சம் நம்பிக்கை
என்ன மாறியதுCIT(Appeals) Pune dismissed or only partly allowed appeals filed by Krsnaa Diagnostics across seven assessment years, upholding tax demands totaling ₹62.69 Cr.
ஏன் இது முக்கியம்The ₹62.69 Cr demand is significant relative to annual profitability (~64% of TTM PAT of ₹98 Cr); an adverse outcome or mandatory deposit requirements could strain liquidity.
Aggregate disputed demand: ₹62,69,17,435Disputed demand vs TTM PAT: ~64%Disputed demand vs Net worth: ~6.3%Assessment years involved: AY 2017-18 to AY 2023-24
📅 குறுகிய காலம்May create negative sentiment around potential tax liabilities and cash outflows if pre-deposit amounts are mandated during ITAT appeal filings.
📈 நீண்ட காலம்Tax litigation before ITAT often takes extended periods; the ultimate outcome will determine whether provisions or write-offs are required.
⚠ அபாய எச்சரிக்கைகள்
Adverse tax dispute outcome
Potential requirement to pre-deposit 20% of disputed tax demand before ITAT stay
Material impact on cash flow relative to TTM PAT
👀 கவனிக்க வேண்டியவை
Track the timeline of filings and stay applications before the ITAT, and watch for any provisioning or contingent liability disclosures in the upcoming quarterly financial results.
Krsnaa Diagnostics: Corrigendum on 16.21 Lakh Promoter Warrants; Stake to Rise to 29.70%
Krsnaa Diagnostics issued a corrigendum to its Postal Ballot Notice following directives from the NSE regarding its proposed preferential issue of share warrants. Under the proposal, 16,21,000 warrants will be allotted to promoter entities, including Mr. Rajendra Khivraj Mutha (75,000) and Krsna Diagnostics (Mumbai) Pvt Ltd (15,46,000). Upon full warrant exercise and ESOP dilution, the promoter and promoter group holding will increase from 27.11% to 29.70% across an expanded base of 3,50,65,279 shares. The e-voting process for shareholder approval is open until September 17, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுProvided expanded disclosures on promoter allottees, beneficial ownership, and post-issue capital structure per NSE review.
ஏன் இது முக்கியம்Increases promoter commitment and equity ownership from 27.11% to 29.70%, injecting fresh equity capital into the company.
Warrants proposed: 16,21,000Pre-issue promoter holding: 27.11%Post-issue promoter holding: 29.70%Post-issue share count (fully diluted): 3,50,65,279E-voting end date: செப்டம்பர் 17, 2026
📅 குறுகிய காலம்Ensures regulatory compliance ahead of the postal ballot closure on September 17, 2026, with minimal short-term price impact.
📈 நீண்ட காலம்Strengthens capital structure and aligns promoter incentives through higher equity ownership without triggering open offer obligations.
⚠ அபாய எச்சரிக்கைகள்
Minor equity dilution of non-promoter shareholding from 72.89% to 70.30%.
👀 கவனிக்க வேண்டியவை
Track the shareholder voting results on September 17, 2026, and watch for final regulatory approvals and warrant exercise pricing details.
Krsnaa Diagnostics receives additional Income Tax demand of ₹12.10 Cr for AY 2022-23
Krsnaa Diagnostics received a rectification order under Section 154 read with Section 143(3) of the Income Tax Act, 1961 for AY 2022-23 from the ACIT, Pune. The order recomputes tax under Section 115BBE, raising the total balance payable from ₹19.63 Cr to ₹31.73 Cr, creating an additional demand of ₹12.10 Cr (~12.3% of TTM PAT). Total assessed income remains unchanged at ₹98.27 Cr. The company plans to file an appeal and rectification against the additional demand, having already contested the original assessment.
உச்சம் நம்பிக்கை
என்ன மாறியதுIncome Tax Department issued a rectification order increasing the tax demand for AY 2022-23 by ₹12.10 Cr due to the application of Section 115BBE tax rates.
ஏன் இது முக்கியம்The revised total demand of ₹31.73 Cr represents ~32.4% of TTM PAT (₹98 Cr), posing a potential financial liability if appellate proceedings are unfavorable.
Additional tax demand: ₹12,09,98,110Revised total tax payable: ₹31,73,28,734Total assessed income: ₹98,27,29,935Additional demand vs TTM PAT: ~12.3%Total revised demand vs TTM PAT: ~32.4%
📅 குறுகிய காலம்Negative sentiment due to the unexpected tax liability; however, an appeal will defer immediate cash outflows pending appellate review.
📈 நீண்ட காலம்Limited operational impact, though adverse resolution could lead to cash outflow and write-offs impacting net profit.
⚠ அபாய எச்சரிக்கைகள்
Adverse tax dispute outcome leading to cash outflow of up to ₹31.73 Cr
Potential for interest/penalty accruals pending final appellate resolution
👀 கவனிக்க வேண்டியவை
Track the outcomes of the appeal filed before the appellate authority and any potential cash flow impact or tax provisioning in upcoming quarterly results.
Krsnaa Diagnostics to raise ₹91.75 Cr via preferential issue of warrants at ₹566/share
Krsnaa Diagnostics has announced the terms of a preferential issue of up to 16,21,000 convertible warrants at an issue price of ₹566 per warrant, aggregating to ₹91.75 crore. The warrants are proposed to be allotted to Mr. Rajendra Mutha (75,000 warrants for ₹4.25 crore) and Krsnaa Diagnostics (Mumbai) Private Limited (15,46,000 warrants for ₹87.50 crore). Each warrant is convertible into one equity share within an 18-month period. The total fundraise represents approximately 5.2% of the company's market capitalisation (₹1,757 crore) and comes at a premium to the current market price of ₹540.30.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal disclosure of preferential warrant allotment terms, issue price (₹566), and investor allocation totaling ₹91.75 crore.
ஏன் இது முக்கியம்Demonstrates promoter capital commitment at a premium to current market price, infusing growth capital and strengthening the balance sheet.
Total fundraise amount: Rs. 91,74,86,000Fundraise vs Market cap: ~5.2%Issue price per warrant: INR 566Total warrants: 16,21,000Conversion window: 18 மாதங்கள்
📅 குறுகிய காலம்Positive sentiment likely due to insider participation at an issue price above the current market price of ₹540.30.
📈 நீண்ட காலம்Provides equity funding to support ongoing PPP projects and retail expansion without increasing long-term debt leverage.
⚠ அபாய எச்சரிக்கைகள்
Dilution to minority shareholders upon full conversion
Dependency on full warrant conversion within 18 months for complete cash inflow
👀 கவனிக்க வேண்டியவை
Track shareholder/EGM approval outcome, receipt of the initial 25% warrant subscription amount, and clarity on end-use of proceeds towards capex/debt reduction in upcoming quarterly briefings.
Krsnaa Diagnostics seeks shareholder nod for Rs 91.75 Cr warrant issue to promoters at Rs 566/share
Krsnaa Diagnostics has issued a postal ballot notice seeking shareholder approval to issue up to 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group. The warrants are priced at Rs 566 per share (face value Rs 5 + Rs 561 premium), raising up to Rs 91.75 Cr, which represents ~5.1% of its current market cap of Rs 1,792 Cr. The issue price is slightly above the current market price of Rs 551. Remote e-voting is scheduled from August 19, 2026, to September 17, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company formally initiated postal ballot proceedings to approve a preferential issue of 16.21 lakh convertible warrants to the promoter group at Rs 566 per warrant.
ஏன் இது முக்கியம்Demonstrates promoter commitment by injecting up to Rs 91.75 Cr in equity capital at a price above prevailing market rates, potentially raising promoter holding from the current 27.11% and supporting ongoing PPP expansion capex.
Total fundraise value: Rs 91,74,86,000Warrants offered: 16,21,000Issue price per warrant: Rs 566Fundraise vs Market cap: ~5.1%E-voting cut-off date: ஆகஸ்ட் 14, 2026
📅 குறுகிய காலம்Likely to support market sentiment in the near term as promoters are infusing capital at Rs 566 per share, above current trading levels.
📈 நீண்ட காலம்Provides long-term equity capital to strengthen the balance sheet (current debt Rs 531 Cr) and support expansion into new state PPP contracts and retail diagnostics.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~4.8% on fully diluted equity base upon warrant conversion
Warrant funds are received in tranches (25% upfront, 75% over up to 18 months)
👀 கவனிக்க வேண்டியவை
Track shareholder voting results after September 17, 2026, followed by stock exchange in-principle approvals and receipt of the mandatory upfront 25% warrant subscription amount.
22% Revenue Growth in Q1 FY27; Retail Segment Surges 64% YoY to Rs 19.3 Cr
Krsnaa Diagnostics reported a 22% YoY revenue growth to Rs 235.5 Cr for Q1 FY27, driven by the ramp-up of the Rajasthan contract and strong retail performance. However, PAT declined 19% YoY to Rs 16.6 Cr, and EBITDA margins contracted by 221 bps to 25% due to upfront fixed costs in Rajasthan. The retail segment showed significant momentum, with its revenue contribution rising to 8% of the total, up from 1% in the previous year. The company maintains a robust order book with over 200 CT/MRI centers planned for completion.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is transitioning from a purely PPP-driven model to a hybrid model with an increasing retail footprint (8% of revenue) and is currently absorbing high upfront costs for its Rajasthan expansion.
ஏன் இது முக்கியம்While top-line growth remains strong, the temporary margin compression and PAT decline reflect the execution risks of large-scale government contracts. The shift toward retail is critical for long-term margin stability and reducing receivable risks.
Q1 FY27 Revenue: Rs 235.5 கோடிQ1 வருவாய் vs TTM வருவாய்: 30.4%Retail Revenue Growth: 64%EBITDA லாப வரம்பு: 25%Q1 FY27 PAT: Rs 16.6 கோடி
📅 குறுகிய காலம்The stock may face pressure due to the 19% YoY decline in PAT and margin contraction, despite healthy revenue growth.
📈 நீண்ட காலம்The structural shift toward a 20% retail revenue target by FY27 and the scale-up of the Rajasthan contract are positive long-term drivers if margins normalize.
⚠ அபாய எச்சரிக்கைகள்
Margin compression from upfront expansion costs
Stretched receivables from government entities
High client concentration in government health departments
👀 கவனிக்க வேண்டியவை
Monitor the utilization levels and margin recovery in the Rajasthan project over the next two quarters. Watch for the company's ability to maintain retail growth momentum and improve cash conversion from government contracts.
Krsnaa Diagnostics reported a 22% YoY revenue growth to ₹235.5 Cr for Q1 FY27, primarily driven by the operationalization of the Rajasthan pathology network. The Rajasthan project contributed ₹25.7 Cr (approx. 11% of quarterly revenue) with 1,321 units now operational. However, PAT declined 19% YoY to ₹16.6 Cr as EBITDA margins contracted from 27% to 25% due to upfront fixed costs of new infrastructure. The Board also approved a preferential warrant issue to promoters, signaling internal backing as the company scales its retail and PPP segments.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe massive Rajasthan pathology contract has transitioned from the implementation phase to active operations, and the company has initiated a fundraise from promoters via share warrants.
ஏன் இது முக்கியம்Rajasthan is a critical growth engine for Krsnaa; its successful scale-up is vital for hitting FY27 targets. The promoter warrant issue provides capital for expansion while signaling management's commitment despite recent margin pressure.
Q1 வருவாய்: ₹235.5 கோடிRajasthan Revenue Contribution: ₹25.7 கோடிQ1 வருவாய் vs TTM வருவாய்: 30.5%Retail Revenue Growth: 64% YoYEBITDA லாப வரம்பு: 25%
📅 குறுகிய காலம்The stock may face pressure due to the YoY decline in PAT and margin contraction, though the strong top-line growth and Rajasthan operationalization provide a fundamental floor.
📈 நீண்ட காலம்The structural expansion into Rajasthan and the growth of the high-margin retail segment (targeting 20% of revenue by FY27) could significantly re-rate the business as fixed costs are absorbed by higher volumes.
⚠ அபாய எச்சரிக்கைகள்
Margin compression due to high upfront fixed costs
Dilution risk from the upcoming preferential warrant issue
High dependency on government (PPP) contracts and associated receivable risks
👀 கவனிக்க வேண்டியவை
Monitor the utilization ramp-up in the Rajasthan and Maharashtra projects over the next two quarters to see if operating leverage restores PAT margins to the 10-12% range. Investors should also watch for the specific pricing and size of the promoter warrant issue once detailed terms are disclosed.
Krsnaa Q1 Revenue up 22% to ₹235.5 Cr; Promoter to Infuse Capital via Warrants at ₹565
Krsnaa Diagnostics reported a 22% YoY revenue growth in Q1 FY27 to ₹235.53 Cr, driven by its expanding PPP footprint. However, Net Profit (PAT) declined by 19.3% YoY to ₹16.55 Cr, impacted by higher finance costs and hospital fees. The board approved a preferential issuance of 16.21 lakh warrants to promoters at ₹565 per share (a premium to the current market price), potentially raising ~₹91.6 Cr. A significant monitorable remains the ₹62.69 Cr income tax demand currently under appeal, which represents over 60% of the company's TTM PAT.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results and announced a fresh capital infusion from promoters via warrants at a premium to the current market price.
ஏன் இது முக்கியம்The revenue growth confirms the company's ability to win and execute large government tenders, but the PAT decline and tax litigation highlight operational and regulatory risks.
Q1 வருவாய்: ₹235.53 கோடிQ1 PAT: ₹16.55 கோடிWarrant Issue Price: ₹565Tax Demand vs TTM PAT: 61.6%Dividend per share: ₹2.00
📅 குறுகிய காலம்The stock may face pressure due to the YoY decline in PAT and the large tax demand, though the promoter warrant pricing at ₹565 may provide a psychological floor.
📈 நீண்ட காலம்Long-term value depends on the company's ability to transition its revenue mix toward 20% retail by FY27 and resolve stretched receivables in states like Himachal Pradesh and Karnataka.
⚠ அபாய எச்சரிக்கைகள்
Material income tax demand of ₹62.69 Cr
Stretched receivables from government health departments
Margin compression in the current quarter
👀 கவனிக்க வேண்டியவை
Monitor the scale-up of the Rajasthan and Maharashtra contracts to see if margins recover from the current 24.6% level. Investors should also track the progress of the income tax appeals as the demand is material relative to annual profits.
KRSNAA expands Himachal footprint with 34 CT Scan centers under new 7-year PPP agreement
Krsnaa Diagnostics has significantly scaled its operations in Himachal Pradesh, increasing its scope from 12 to 34 CT Scan centers under a new Public Private Partnership (PPP) agreement. The contract is for an initial 7-year term, extendable by 3 years, and will operate on a majority cash basis. This expansion adds 22 new centers to the company's existing radiology network of 186 CT/MRI centers, representing a ~12% increase in total radiology capacity. The shift to a 'cash basis' model is particularly notable given the company's historical challenges with stretched government receivables in this state.
உச்சம் நம்பிக்கை
என்ன மாறியதுKrsnaa has transitioned from a 12-center arrangement to a much larger 34-center long-term contract in Himachal Pradesh, nearly tripling its presence in the state.
ஏன் இது முக்கியம்Himachal Pradesh is a key revenue contributor where receivables were previously stretched; scaling up on a cash basis secures long-term revenue visibility while potentially improving the company's working capital cycle.
New Center Count: 34Incremental Centers: 22Contract Tenure: 7 yearsCapacity Increase (vs 186 existing): ~11.8%TTM வருவாய்: ₹773 கோடி
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as it demonstrates contract stickiness and significant scale-up in a core geography.
📈 நீண்ட காலம்This provides a decade of revenue visibility for the radiology segment and validates the company's ability to renew and expand government tenders despite operational challenges.
⚠ அபாய எச்சரிக்கைகள்
Execution risks in hilly terrain
Historical stretched receivables from government entities
Dependency on global OEMs for equipment maintenance
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline for the 22 additional centers and observe if the 'cash basis' clause effectively reduces the days sales outstanding (DSO) for the Himachal Pradesh cluster in upcoming quarterly results.
ICRA Reaffirms [ICRA]A (Stable) Rating for Rs 304.15 Cr Bank Facilities
ICRA has reaffirmed Krsnaa Diagnostics' long-term rating at [ICRA]A with a Stable outlook and its short-term rating at [ICRA]A1. The total rated bank facilities amount to Rs 304.15 crore, which includes Rs 166.60 crore in long-term and Rs 137.55 crore in short-term limits. This rated amount represents approximately 57% of the company's total debt of Rs 531 crore. The rating action includes assignments for enhanced amounts, indicating the company is securing higher credit limits to support its expansion in Rajasthan and Maharashtra.
உச்சம் நம்பிக்கை
என்ன மாறியதுICRA has reaffirmed the company's credit ratings while extending the coverage to an increased total facility amount of Rs 304.15 crore.
ஏன் இது முக்கியம்Maintaining an 'A' rating ensures the company can continue to access debt at competitive rates, which is vital for its capital-intensive business model of setting up diagnostic centers under government tenders.
Total Rated Amount: Rs 304.15 கோடிLong-term Rating: [ICRA]A (Stable)Short-term Rating: [ICRA]A1Rated Debt vs Total Debt: ~57%Total Debt: Rs 531 கோடி
📅 குறுகிய காலம்The reaffirmation provides stability and confirms that the company's credit profile remains healthy despite recent stock price pressure.
📈 நீண்ட காலம்The enhanced limits for bank guarantees support the company's long-term strategy of aggressive expansion in the PPP segment across new states.
⚠ அபாய எச்சரிக்கைகள்
High concentration of receivables from government health departments
Stretched receivables in Himachal Pradesh and Karnataka
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to convert the enhanced bank guarantee limits into successful PPP project executions, particularly the large Rajasthan contract which is key to FY26 growth.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
